The next phase, expected to occur in-may or June 2008, will determine whether Illumina’s infringement was willful. Affymetrix in addition has requested injunctive relief in cases like this, and can ask that the Courtroom take up this demand once the patents are located to be valid. Affymetrix has developed among the industry’s strongest patent portfolios, featuring more than 400 patents granted in the U.S. And more than 40 patents granted in Europe. The business continues to license its technology under suitable conditions to stimulate the wide commercialization of genome analysis technologies. To view today’s filings, please check out: Affymetrix management will be discussing this litigation through the third one fourth operating results conference call at 2:00 p.m.Edelman says that while far less rich industrialized countries have committed to end child poverty, america is usually sliding backwards. For more information, please browse Defining Poverty and Why It Matters for Children available online.
Gain access to submits additional patent applications for Cobalamin-mediated oral medication delivery technology Gain access to PHARMACEUTICALS, INC. , a biopharmaceutical company leveraging its proprietary drug-delivery platforms to build up treatments in areas of oncology, malignancy supportive diabetes and treatment, announced it has submitted extra patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of several global top-100 injectable drugs, due to the growing curiosity surrounding the company’s proprietary oral delivery technology.